Vanderbilt University Syndax Pharmaceuticals Inc Transaction History
Vanderbilt University
- $480 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
195Shares Held
90MCall Options Held
353KPut Options Held
207K-
Black Rock Inc. New York, NY7.55MShares$156 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.44MShares$154 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.66MShares$117 Million14.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.93MShares$102 Million0.0% of portfolio
-
State Street Corp Boston, MA4.82MShares$99.6 Million0.01% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.17B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...